Cannabis hilft bei Übelkeit

Eine unkontrollierte Fallstudie aus dem Jahr 1989 untersuche die Wirkung von Nabilone (ein synthetische THC Kopie) bei Übelkeit und Erbrechen im Zusammenhang mit HIV / AIDS. Die Studie ergab, dass Nabilone die Übelkeit und das Erbrechen verringert. US Naional Library of Medicine

In einer kontrollierten Studie im Jahr 2010 wurde festgestellt, dass Cannabis besser in der Reduzierung von Übelkeit und Erbrechen wirkt als ein Placebo und andere Medikamente. Getestet wurde dies bei Krebspatienten, die eine Chemotherapie machen. British Pharmacological Society

In einer 2008 durchgeführten Studie wurde festgestellt, dass THC und Nabilone (THC-Medikament) den Appetit erhöhen und außerdem Übelkeit und Erbrechen verringern. Canadian Journal of Gastroenterology

In einer 2006 durchgeführten Umfrage wurde festgestellt, dass Cannabis effektiv ist gegen Übelkeit und Erbrechen. US National Library of Medicine

In einer 1994 durchgeführten Studie wurde festgestellt, dass Nabilone (THC-Medikament) genau so effektiv ist wie das Anti-Brech-Medikament Metoclopramid. British Journal of Anaesthesia

Comparative trail of the antiemetic effects of THC and haloperidol. Von Neidhart, Gagen, Wilson, Young im Int J Clin Pharmacol Res 1981; 21: S.38-42

Ameriloration of cancer chemothera-induced nausea and vomiting by delta-0-tetrahydrocannabinol. Von Ekert, Waters, Jurk, Mobilia, Lounghnan im Med J Aust 1979; 2: S. 657-659

Tetrahydrocannabinol (THC) plus prochlorperazine (PCZ) for refractory nausea and vomiting (N/V). Von Artim, DiBella im Proc Am Soc Clin Oncol 1983; 2: S.84

Delta-9-tetrahydrocannabbinol as an antiemetics for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo. Von Frytak, Moertel, O´Fallon, Rubin, Creagan, O´Connel im Ann Int Med 1070; 91: S. 825-830

A double-blind, controlled trial of nabilone vs prochlorperazine for refractory emesis induced by cancer chemotherapy. Von Johansson, Kilkku, Groenross im Can Treat Rev 1982; 9: S. 25-33

Nabilone vs placeno in the treatment of chemotherapy-induced nausea and vomiting in cancer patients. Von Levitt im Can Treat Rev 1982; 9: S. 49-53

Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a double-blind, crossover trial. Von Chan, Correia, MacLead im Pediatrics 1987; 79: S. 946-952

Nabilone: An alternative antiemetic for cancer chemotherapy. Von Dalzell, Bartlett, Lilleyman im Arch Dis Child 1986; 61: S. 502-505

Randomizied double blind comparison of delta-9-tetrahydrocannabinol (THC) and marijuana as chemotherapy antiemetics. Von Levitt, Faiman, Hawks, Wilson im Proc Am Soc Clin Oncol 1984; 3: S. 91

Antiemetics in patients receiving chemotherapy for cancer. A randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine. Von Sallan, Cronin, Zelen, Zinberg im N Engl J Med 1980; 302: S- 135-138

Antimetic therapy: a review of recent studies and a report of a random assignment trial comparing metoclopramide with delta-9-tetrahydrocannabinol. Von Gralla, Tyson, Bordin, Clark, Kelsen, Kris im Can Treat Rep 1984; 68: S. 163-172

Cannabis and cancer chemotherapy. A comparison of oral delta-9-THC and prochlorperazine. Von Ungerleider, Andry, Fairbanks, Goodniught, Sarna, Jamison im Cancer 1982; 50: S. 636-645

Dronabinol and prochlorperazne in combination for treatment of cancer chemotherapy-induced nausea and vomititng. Von Lane, Vogel, Ferguson, Krasnow, Saiers, Hamm im J Pain Sym Manag 1991; 6: S. 352-359

Preliminary efficacy and safety of an oromucosal standaridized cannabis extract in chemothreapy-induced nausea and vomiting. Von Duran, Pérez, Abanades im Br J Clin Pharmacol 2010; 70(5): S. 656-663

Dose vs response of tetrahydroannabinol (THC) vs prochlorperazine as chemotherapy antiemetics. Von Levitt, Wilson, Bowman, Faiman, Kemel, Krepart im Proc Am Soc Clin Oncol 1981; 22: S. 422

The antiementic activity of tetrahydrocannabinol versus metoclopramide and thiethylperazine in patients undergoing cancer chemotherapy. Von Colls, Ferry, Gray, Harvey, McQueen im N Z Med J 1980; 91: S. 449-451

Efficacy of terahydrocannabinol in patients refractory to standard anti-emetic therapy. Von McCabe, Smith, Goldberg, Macdonalds, Woolley, Warren im Invest New Drugs 1988; 6: S. 243-246

Superiority of nabilone over prochlorperazine as an antiemetic in patiens receiving cancer chemotherapy. Von Herman, Einhorn, Jones im N Engl J Med 1979; 300: S. 1295-1297

Nabilone and metoclopramide in the treatment of nausea and vomiting due to cisplatinum: a double blind study. Von Crawford, Buckman im Med Oncol Tumour Pharmacother 1986; 3: S. 39-42

A cross-over comparison of nabilone and prochlorperazine for emesis induced by cancer chemotherapy. Von Niiranen, Mattson im Am J Clin Oncol 1985; 8 : S. 336-340

A multi-institutional phase III study of nabilone vs placebo in chemotherapy-induced nausea and vomiting. Von Jones, Durant, Greco, Robertone im Can Treat Rev 1982; 9: S. 45-48

A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopradmide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues. Von Cunningham, Bradley, Forrest im Eur J Can Clin Oncol 1988; 24: S. 685-689

THC or Compazine for the cancer chemotherapy patient – the UCLA study. Part II patient drug preference. Von Ungerleider, Sarna, Fairbanks, Goodnight, Andrysiak, Jamison im Am J Clin Oncol 1985; 8: S. 142-147

Antiemetic effect of terahydrocannabinol. Compared with placebo and prochloperazine in chemotherapy-associated nauseo and emesis. Von Orr, McKernan, Bloome im Arch Int Med 1980; 302: S. 1431-1433

D9-tetrahydrocannabinol (THC) as an antiemetic in patients treated with cancer chemotherapy; a double-blind cross-over trial against placebo. Von Kluin-Nelemans, Nelemans, Meuwissen, Maes im Vet Hum Toxicol 1979; 21: S. 338-340

Antiemnetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. Von Sallan, Zinberg, Frei im N Engl J Med 1975; 293: S. 795-797

Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy. Von Ahmedzai, Carlyle, Clader, Moran im Br J Cancer 1983; 48: S. 657-663

Effcacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Von Meiri, Jhangiani, Vredenburgh im Curr Med Res Opin 2007; 23(3): S. 553-543

Delta-9-tetrahydrocannabinol as an antiemetics in cancer patients receiving high-dose methotrexate. Von Chang, Shilling, Stillman, Goldberg, Seipp, Barofsky im Ann Int Med 1979; 91: S. 819-824

A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy. Von Chang, Shilling, Stillman im Cancer 1981; 47: S. 1746-1751

Nabilone: an effective antiemetic in patients receiving cancer chemotherapy. Von Einhorn, Nagy, Furnas, Williams, im J Clin Pharmacol 1981; 21: S. 64-69

Nabilone: antiemetic crossover study in cancer chemotherapy patients. Von Nagy, Furnas, Einhorn, Bond im Proc Am Soc Can Res 1978; 19: S.30

Crossover comparison of the antiemetic efficacy of nabilone and alizapride in patients with nonseminomatous testicular cancer receiving cisplatin therapy. Von Niederle, Schutte, Schmidt im Klin Wochenschr 1986; 64: S. 362-365

Prospective randomized double-blind trail of nabilone versus domperidone in the treatment of cytotxic-induced emesis. Von SPomeroy, Fennelly, Towers im Can Chemother Pharmacol 1986; 17: S. 285-288

Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis. Von Steele, Gralla, Braun, Young im Can Treat Rep 1980; 64: S. 219-224

Double-blind, randomized, crossover trail of nabilone vs. placebo in cancer chemotherapy. Von Wada, Bogdon, Gunnell, Hum, Gota, Rieth im Cancer Treatment Rev. 1982; 9: S. 39-44

Randomized comparative trail of a new anti-emetic: nabilone, in cancer patients treated with cisplantin.Von George, Pejovic, Thuaire, Kramer, Wolff im Biomed Pharmacother 1983; 37: S. 24-27

Dose ranging evaluation of the antiemetic efficacy and toxicity of intramuscular levonantradol in cancer subject with chemotherapy-induced emesis. Von Stambaugh, McAdams, Vreeland im Int J Clin Pharmacol Res 1984; 24: S. 480-485

A randomized multicenter single blind comparison of a cannabinoid anti-emetic (levonantradol) with ychlorpromazine in patients receiving their first cytotoxic chermotherapy. Von Hutcheon, Palmer, Soukop im Eur J Can Clin Oncol 1983; 19: S. 1087-1090